Metformin Hydrochloride Tablet, Extended Release
FDA Label NDC 69238-2125

35 label sections · Submitted to the FDA by Amneal Pharmaceuticals Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Amneal Pharmaceuticals Llc for the product Metformin Hydrochloride (NDC 69238-2125). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: lactic acidosis, 1 indications and usage, 2.2 recommended dosage for metformin hydrochloride extended-release tablets in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, 2.3 switching between metformin hydrochloride immediate-release tablets and metformin hydrochloride extended-release tablets, 2.4 recommended dosage in patients with renal impairment, 2.5 discontinuation for iodinated contrast imaging procedures, 3 dosage forms and strengths, 4 contraindications, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.